-
101.发明授权
公开(公告)号：US5888984A
公开(公告)日：1999-03-30
申请号：US241692
申请日：1994-05-12
申请人： Harold G. Brown
发明人： Harold G. Brown
IPC分类号： A61K8/73 , A61K8/92 , A61K9/00 , A61K31/715 , A61K31/727 , A61K31/728 , A61K31/737 , A61K36/15 , A61K36/185 , A61K36/23 , A61K36/45 , A61K36/53 , A61K36/534 , A61K36/537 , A61K36/54 , A61K36/57 , A61K36/61 , A61K36/736 , A61K36/752 , A61K36/886 , A61K36/9064 , A61K36/9066 , A61K47/44 , A61Q19/00 , A61K31/70 , A61K31/725 , A61K35/78
CPC分类号： A61K47/44 , A61K31/715 , A61K31/727 , A61K31/728 , A61K31/737 , A61K36/15 , A61K36/185 , A61K36/23 , A61K36/45 , A61K36/53 , A61K36/534 , A61K36/537 , A61K36/54 , A61K36/57 , A61K36/61 , A61K36/736 , A61K36/752 , A61K36/886 , A61K36/9064 , A61K36/9066 , A61K8/73 , A61K8/735 , A61K8/922 , A61K9/0014 , A61K9/0019 , A61Q19/00 , Y10S424/13 , Y10S514/825 , Y10S514/859 , Y10S514/862 , Y10S514/865 , Y10S514/885 , Y10S514/886 , Y10S514/887
摘要： The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.
-
公开(公告)号：US5885597A
公开(公告)日：1999-03-23
申请号：US942184
申请日：1997-10-01
申请人： Jonah Botknecht , Robert Fishman
发明人： Jonah Botknecht , Robert Fishman
CPC分类号： A61K31/77 , A61K31/165 , A61K31/167 , A61K31/192 , A61K31/245 , A61K31/573 , A61K9/0014 , Y10S514/817 , Y10S514/825 , Y10S514/886 , Y10S514/887 , Y10S514/944 , Y10S514/946 , Y10S514/947
摘要： Disclosed is a topical composition for relieving pain in a person in need of such relief, consisting essentially of an effective amount of a combination of at least one corticoid analgesic, at least one arylpropionic acid type analgesic, and at least one p-aminobenzoic acid ester type local anesthetic; an amount effective in enhancing the effectiveness in relieving pain of the combination of capsaicin, and an amount effective to increase the transmission thereof of through the skin of at least one phospholipid and at least one polyoxyethylenepolyoxypropylene copolymer.
摘要翻译： 公开了一种用于缓解需要这种缓解的人的疼痛的局部组合物，其基本上由有效量的至少一种皮质激素止痛剂，至少一种芳基丙酸类止痛剂和至少一种对氨基苯甲酸酯的组合组成 型局麻药; 有效提高缓解辣椒素组合的疼痛的有效性的量，以及有效增加其至少一种磷脂和至少一种聚氧乙烯聚氧丙烯共聚物通过皮肤的透过量的量。
-
公开(公告)号：US5872118A
公开(公告)日：1999-02-16
申请号：US549686
申请日：1995-12-18
申请人： James Leroy Kelley , Gregory Cooksey Rigdon , Barrett Randolph Cooper , Ed Williams McLean , David Lee Musso , Gloria Faye Orr , Jeffrey Leaman Selph , Virgil Lee Styles
发明人： James Leroy Kelley , Gregory Cooksey Rigdon , Barrett Randolph Cooper , Ed Williams McLean , David Lee Musso , Gloria Faye Orr , Jeffrey Leaman Selph , Virgil Lee Styles
IPC分类号： C07D295/18 , A61K31/16 , A61K31/165 , A61K31/35 , A61K31/352 , A61K31/353 , A61K31/535 , A61K31/5375 , A61P21/02 , A61P25/02 , A61P25/04 , A61P25/08 , A61P25/20 , A61P25/22 , A61P29/00 , C07C231/02 , C07C233/11 , C07C233/22 , C07C233/51 , C07C235/34 , C07C235/36 , C07C235/78 , C07C255/57 , C07C259/06 , C07D215/12 , C07D215/14 , C07D223/16 , C07D295/185 , C07D311/58
CPC分类号： C07D223/16 , C07C233/11 , C07C233/22 , C07C235/34 , C07C235/36 , C07C235/78 , C07C255/57 , C07C259/06 , C07D215/14 , C07D295/185 , C07D311/58 , C07C2101/02 , C07C2101/04 , C07C2101/08 , C07C2101/14 , C07C2102/08 , C07C2102/10 , Y10S514/825 , Y10S514/886 , Y10S514/906
摘要： Novel compounds of formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each selected from hydrogen and fluoro and at least one and not more than two is fluoro;R.sup.5 is selected from hydrogen and C.sub.1 -C.sub.4 alkyl;R.sup.6 is selected from hydrogen, C.sub.1 -C.sub.4 ally and hydroxy; orR.sup.5 and R.sup.6 together with the ring carbon form a carbonyl group;R.sup.7 is selected from hydrogen and hydroxy,R.sup.8 and R.sup.9 are each selected from hydrogen, C.sub.1 -C.sub.4 alkyl and cyclo(C.sub.3 or C.sub.4) alkyl or together with the nitrogen form a morpholino group; andX is selected from a bond, methylene and --O-- and is always a bond or --O-- when any of R.sup.5, R.sup.6 and R.sup.7 is other than hydrogen and is always a bond when R.sup.5 and R.sup.6 together with the ring carbon form a carbonyl group;and their salts and solvates have a number of uses as central muscle relaxants. In particular, treatment of conditions associated with abnormally raised skeletal muscle tone. They are of special value in the relaxation of skeletal muscle in spastic, hypertonic and hyperkinetic conditions.
摘要翻译： PCT No.PCT / GB94 / 01003 Sec。 371 1995年12月18日第 102（e）1995年12月18日日期PCT PCT 1994年5月10日PCT公布。 WO94 / 26693 PCT出版物 日期1994年11月24日新颖的式（I）化合物其中R 1，R 2，R 3和R 4各自选自氢和氟，并且至少一个且不多于两个是氟; R5选自氢和C1-C4烷基; R6选自氢，C1-C4烯丙基和羟基; 或R 5和R 6与环碳一起形成羰基; R7选自氢和羟基，R8和R9各自选自氢，C1-C4烷基和环（C3或C4）烷基或与氮一起形成吗啉代基; 并且X选自键，亚甲基和-O-并且当R 5，R 6和R 7中的任何一个不是氢时总是键或-O-，并且当R 5和R 6与环碳一起形成时，它们总是键 羰基; 其盐和溶剂合物具有许多用途作为中枢肌肉松弛剂。 特别是治疗与异常升高的骨骼肌张力相关的病症。 它们在痉挛，高渗和运动过度的条件下对骨骼肌的松弛具有特殊的价值。
-
公开(公告)号：US5859062A
公开(公告)日：1999-01-12
申请号：US471124
申请日：1995-06-06
申请人： Marina Bianchi , Anthony Cerami , Kevin J. Tracey , Peter Ulrich
发明人： Marina Bianchi , Anthony Cerami , Kevin J. Tracey , Peter Ulrich
IPC分类号： C07D233/61 , A61K31/00 , A61K31/155 , A61K31/167 , A61K31/17 , A61K31/175 , A61K31/195 , A61K31/198 , A61K31/415 , A61K31/4164 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61K31/60 , A61P3/00 , A61P9/00 , A61P29/00 , A61P31/00 , A61P33/00 , A61P35/00 , A61P43/00 , C07C275/38 , C07C275/40 , C07C281/18 , C07D213/42 , A61K31/165
CPC分类号： A61K31/621 , A61K31/00 , A61K31/155 , A61K31/167 , A61K31/17 , A61K31/175 , A61K31/195 , A61K31/4164 , A61K31/44 , A61K31/60 , C07C275/38 , C07C275/40 , C07C281/18 , Y10S514/825 , Y10S514/886 , Y10S514/903
摘要： This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.
-
公开(公告)号：US5859003A
公开(公告)日：1999-01-12
申请号：US691415
申请日：1996-08-02
申请人： Helmut Hettche , Reinhard Muckenschnabel , Gerhard Scheffler , Ilona Fleischhauer , Wolfgang Morick
发明人： Helmut Hettche , Reinhard Muckenschnabel , Gerhard Scheffler , Ilona Fleischhauer , Wolfgang Morick
CPC分类号： C07D403/04 , A61K31/55 , Y10S514/863 , Y10S514/886 , Y10S514/887
摘要： The present invention relates to salts of azelastine having improved solubility in water. The salts of the present invention are prepared by reacting azelastine with acetic acid, gluconic acid, lactic acid or malic acid. A pharmaceutical composition may be prepared containing an azelastine salt and a pharmaceutically-acceptable carrier or diluent therefor. The pharmaceutical composition is useful in the treatment of allergies, asthma, inflammatory and psoriasis disorders and provides a cytoprotective effect.
摘要翻译： 本发明涉及在水中具有改善的溶解性的氮卓斯汀盐。 本发明的盐通过将萘曲斯汀与乙酸，葡萄糖酸，乳酸或苹果酸反应来制备。 可以制备药物组合物，其含有氮卓斯坦盐及其药学上可接受的载体或稀释剂。 药物组合物可用于治疗过敏，哮喘，炎性和银屑病，并提供细胞保护作用。
-
公开(公告)号：US5852002A
公开(公告)日：1998-12-22
申请号：US462147
申请日：1995-06-05
IPC分类号： A61K31/34 , A61K20060101 , A61K9/00 , A61K31/12 , A61K31/136 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/282 , A61K31/375 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/505 , A61K31/5415 , A61K31/56 , A61K31/70 , A61K31/7034 , A61K31/706 , A61K31/715 , A61K38/00 , A61K38/21 , A61K45/00 , A61K45/06 , A61K47/00 , A61K47/36 , A61P5/24 , A61P9/00 , A61P11/08 , A61P17/00 , A61P29/00 , A61P35/00 , A61P37/00 , C08B37/08
CPC分类号： A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/503 , A61K31/5415 , A61K31/616 , A61K31/715 , A61K31/728 , A61K45/06 , A61K47/36 , A61K47/4823 , A61K9/0014 , Y10S514/886 , Y10S514/887
摘要： A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
-
107.发明授权Topical ointment consisting of animal fat, plantain lancetowata, and calendula and methods of producing the same 失效由动物脂肪，车前草和金盏花组成的局部软膏及其生产方法
公开(公告)号：US5843467A
公开(公告)日：1998-12-01
申请号：US679583
申请日：1996-07-15
申请人： Wieslaw Ambroziewigz
发明人： Wieslaw Ambroziewigz
CPC分类号： A61K9/06 , A61K35/35 , A61K36/28 , A61K36/68 , Y10S514/886 , Y10S514/887
摘要： A composition for a topically healing ointment having all natural herbs and an animal fat base. The combination of which forms a salve that is active against one or a combination of sources of viral, bacterial and fungus infections that have the ability to penetrate beneath the epidermal layer of the skin.
摘要翻译： 用于具有所有天然草药和动物脂肪基质的局部愈合软膏的组合物。 其组合形成对具有渗透到皮肤表皮层下方的能力的病毒，细菌和真菌感染源的一种或组合的活性的药膏。
-
公开(公告)号：US5843452A
公开(公告)日：1998-12-01
申请号：US252953
申请日：1994-06-02
CPC分类号： A61K38/13 , Y10S514/825 , Y10S514/861 , Y10S514/863 , Y10S514/869 , Y10S514/885 , Y10S514/886 , Y10S514/887
摘要： A composition for use in immunosuppression therapy is disclosed. The composition includes an immunosuppressant drug, such as cyclosporin A, and an ethanol extract of the root xylem of Tripterygium wilfordii. The extract is effective alone, or in combination with such an immunosuppressant, in the treatment of transplantation rejection. Also disclosed is a method of immunosuppression that includes administering to a subject a pharmaceutically effective amount of an immunosuppressant drug and an extract of the type above, in an amount effective to potentiate the action of the drug.
摘要翻译： 公开了用于免疫抑制治疗的组合物。 组合物包括免疫抑制剂药物，如环孢菌素A，以及雷公藤的根木质部的乙醇提取物。 提取物单独有效或与这样的免疫抑制剂组合用于治疗移植排斥反应。 还公开了一种免疫抑制方法，其包括以有效增强药物作用的量向受试者施用药学有效量的上述类型的免疫抑制剂药物和提取物。
-
公开(公告)号：US5830915A
公开(公告)日：1998-11-03
申请号：US918950
申请日：1997-08-26
IPC分类号： A61K31/664 , A61K31/16 , A61K31/38 , A61K31/40 , A61K31/44 , A61K31/66 , A61K31/675 , A61P1/02 , A61P9/00 , A61P17/00 , A61P19/08 , A61P19/10 , A61P27/02 , A61P29/00 , A61P37/00 , A61P43/00 , C07F9/36 , C07F9/572 , C07F9/58 , C07F9/655 , C07F9/6553
CPC分类号： C07F9/588 , C07F9/36 , C07F9/587 , C07F9/655345 , Y10S514/824 , Y10S514/861 , Y10S514/863 , Y10S514/864 , Y10S514/886 , Y10S514/902 , Y10S514/903
摘要： The invention provides compounds which are useful as inhibitors of matrix metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I) ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are described in the claims, a stereoisomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, ester acyloxyamide, imide or derivative thereof. Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by matrix metalloprotease activity using these compounds or the pharmaceutical compositions containing them.
摘要翻译： 本发明提供了可用作基质金属蛋白酶抑制剂的化合物，其有效治疗以这些酶的过量活性为特征的病症。 特别地，本发明涉及具有式（I）结构的化合物，其中R 1，R 2，R 3和R 4在权利要求书中描述，其立体异构体或对映异构体或其药学上可接受的盐，或 生物可水解的烷氧基酰胺，酯酰氧基酰胺，酰亚胺或其衍生物。 还公开了使用这些化合物或含有它们的药物组合物治疗以基质金属蛋白酶活性为特征的疾病的化合物，药物组合物和方法。
-
110.发明授权Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID 失效施用透明质酸和NSAID以降低NSAID的副作用的方法
公开(公告)号：US5811410A
公开(公告)日：1998-09-22
申请号：US465335
申请日：1995-06-05
IPC分类号： A61K31/34 , A61K20060101 , A61K9/00 , A61K31/12 , A61K31/136 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/282 , A61K31/375 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/505 , A61K31/5415 , A61K31/56 , A61K31/70 , A61K31/7034 , A61K31/706 , A61K31/715 , A61K38/00 , A61K38/21 , A61K45/00 , A61K45/06 , A61K47/00 , A61K47/36 , A61P5/24 , A61P9/00 , A61P11/08 , A61P17/00 , A61P29/00 , A61P35/00 , A61P37/00 , C08B37/08
CPC分类号： A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/503 , A61K31/5415 , A61K31/616 , A61K31/715 , A61K31/728 , A61K45/06 , A61K47/36 , A61K47/4823 , A61K9/0014 , Y10S514/886 , Y10S514/887
摘要： A method of administering a medicinal agent and an effective amount of a form of hyaluronic acid for decreasing side effects associated with using the agent alone in treating a disease or condition in mammals is disclosed. The agent may be a non-steroidal anti-inflammatory drug (NSAID). The amount of hyaluronic acid is sufficient enough to provide a dosage greater than 200 mg/70 kg person. The molecular weight of the form of hyaluronic acid may be less than 750,000 daltons.
摘要翻译： 公开了一种施用药剂和有效量的透明质酸形式的方法，用于降低与单独使用该试剂相关的治疗哺乳动物疾病或病症的副作用。 该试剂可以是非甾体抗炎药（NSAID）。 透明质酸的量足以提供大于200mg / 70kg的人的剂量。 透明质酸形式的分子量可以低于750000道尔顿。
-
-
-
-
-
-
-
-
-
搜索结果
996 条记录 (耗时 0.036 秒)
